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labeling index. Additional markers in the eicosanoid pathway are also 
being analyzed. 
Results: To date, a total of 119 subject have been enrolled in the trial 
(the majority of these at the University of Colorado, n=82), with the in-
vestigators remaining blinded in terms of treatment groups. Fluorescent 
bronchoscopy was able to successfully identify areas of mild dysplasia 
or worse in the majority of patients (90/119, 76%). A total of 17 (14%) 
patients had normal bronchial epithelium at all biopsy sites. A wide 
range of endobronchial pathology has been observed in the biopsies, 
with average baseline histology being signiﬁcantly elevated in current 
smokers. When biopsy sites are matched from the ﬁrst and second 
bronchoscopies, changes in histologic grade have been observed, with 
more individual sites showing improvement (n=116) than progression 
(n=72). The subjects are all being scored on histologic outcomes and 
there have been subjects with partial responses, stable disease, and 
progression. In the subset of subjects with Ki-67 analysis (n=49), a sig-
niﬁcant increase in labeling index was associated with smoking status 
(current > former, p=0.006) and worsening histologic grade (p<0.001). 
Immunohistochemical analyses for other markers in the eicosanoid 
pathway (including COX-2, mPGES, PGIS) are currently in progress. 
Conclusions: The iloprost chemoprevention trial continues to progress 
and has proven that our recruitment model can enrich for a population 
of subjects with endobronchial dysplasia. Results are still blinded. The 
treatment has been well tolerated and histologic improvement has been 
observed at speciﬁc biopsy sites in many of the subjects. Analysis of 
endobronchial biopsies for primary and secondary endpoints continues, 
and we are assessing different methodologies for evaluating clinical 
responses in chemoprevention trials (particularly those that could serve 
as a framework for current and future trials).
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Background: Patients at high-risk for the development of lung cancer 
frequently harbor atypical airway epithelium (bronchial dysplasia). 
These lesions are believed to be precursors of invasive lung cancer, 
especially squamous type. However, previous studies of the natural his-
tory of these lesions have been limited by small numbers of specimens 
and short periods of follow-up. We performed an exhaustive analysis 
of all patients enrolled in Colorado SPORE bronchoscopy protocols 
who underwent multiple bronchoscopies to characterize the long-term 
outcome of these lesions.
Methods: SPORE tissue bank records of histologic diagnosis, date of 
bronchoscopy and biopsy site for 121 patients (2,711 biopsies from 
720 unique biopsy sites), who had between two and eight bronchosco-
pies over as many as 11 years were collected. Within subjects, biopsy 
sites from different bronchoscopies were matched and each site was 
classiﬁed into progression, persistent or regression groups. Each site 
was assigned an initial diagnosis according to WHO classiﬁcation 
criteria. Progression, persistence and regression rankings were assigned 
according to whether the biopsy site showed change, or lack thereof, 
from the initial diagnosis to either of four diagnosis groups deﬁned 
as: Non-dysplastic (normal, basal cell hyperplasia and squamous 
metaplasia without atypia); Dysplastic (mild, moderate and severe); 
Carcinoma-in-situ and Invasive carcinoma. In addition to progression 
score, individual bronchoscopies were scored for dysplasia index (DI), 
deﬁned as the number of dysplastic biopsies (including CIS) divided 
by the total number of biopsies per bronchoscopy. Thirty patients with 
multiple brochoscopies had cancer diagnosed at some point during their 
enrollment. In analyses of relationships between bronchial histology 
and development of invasive cancer, an additional 28 patients with a 
single pre-carcinoma bronchoscopy were included.
Results: High grade (HGD: moderate, severe dysplasia and CIS) bron-
chial lesions were more frequently persistent than low grade (LGD: 
mild) lesions (68.5% vs 43.7%, respectively; Chi-square <0.001). 
In addition, both initial and mean DI was higher in persistent versus 
non-persistent (regression) groups for HGD and LGD groups. An-
giogenic squamous dysplasias (ASDs), a subset of dysplastic lesions, 
similarly showed increased persistence of HGD versus LGD lesions 
but additionally showed increased length of persistence in HGD-ASDs 
as compared non-ASD HGDs (25.5 vs. 17.1, respectiviely; p=0.024). 
A similar, non-signiﬁcant trend toward increased length of persistence 
was seen for LGD-ASDs versus non-ASD LGDs. A trend toward 
increased persistence of HGD lesions in patients with all types of 
NSCLC versus no carcinoma patients (80% vs. 65%) was found, and 
this percentage was even higher, though still not statistically differ-
ent, for the subset of patients with squamous cell carcinoma (85%). In 
addition, a trend toward increased mean DI in squamous cell carcinoma 
versus no carcinoma was seen (43% vs 31%).
Conclusions: Analysis of high risk patients undergoing multiple 
bronchoscopies shows a relationship between persistence and degree of 
atypia in bronchial dysplasia. An increase in the length of persistence 
is associated with presence of ASD histology. An association between 
squamous cell carcinoma development and high DI and/or persistence 
of HGD is suggested. These data support the role of bronchial dyspla-
sias as pre-malignant lesions in non-small cell lung cancer.
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Background: Lung cancer causes more deaths than all of the other ma-
jor cancers combined with little improvement in the survival rate over 
the last 25 years. While premalignant lesions for central airway have 
been identiﬁed, the natural history of these lesions is unclear, especially 
for metaplastic lesions. Lung cancer screening of high-risk subjects 
with autoﬂuorescent bronchoscopy (AFB) can reliably detect the pre-
malignant lesions that are precursors to squamous cell carcinoma. 
Methods: A cohort of 350 patients underwent AF bronchoscopy 
(AFB) screening based on lung cancer risk factors at the Lung Cancer 
Screening Clinic at the Roswell Park Cancer Institute in Buffalo NY 
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between the years of 1998-2006. This cohort included patients with two 
or more risk factors for lung cancer, including history of smoking (> 20 
pack years), asbestos exposure, chronic obstructive pulmonary disease 
(COPD), and prior history of aerodigestive cancer. No pre-screening 
with sputum cytology was performed. Follow-up AFB procedures were 
performed on 116 subjects, an average of 11 months after the ﬁrst AFB.
Results: Patients were on average 63 years old, male (66%), and Cau-
casian (94%), 65% with COPD, and never, former, and current smokers 
represented 7%, 63% and 30% respectively. Three biopsies, on average, 
were taken during each bronchoscopy. On the baseline AFB, 53% of 
patients had metaplasia or a higher grade diagnosis; 11% with a dyspla-
sia and 6% with carcinoma in-situ (CIS). Among current smokers, 77% 
had premalignant lesions compared to 45% of the former smokers. In 
regression models, male gender, COPD and current or former smoking 
status were signiﬁcant predictors of lesion detection. On the second 
AFB, 73/116 (63%) had metaplasia or a worse diagnosis; 20% with 
dysplasia or CIS. Premalignant lesions persisted in 82% of patients, 
with 9-25% having higher grade lesions on follow-up. Premalignant 
lesions persisted in former and current smokers (55% and 84% respec-
tively) and in patients with COPD (66%). Male gender, COPD, and 
smoking remained signiﬁcant predictors of persistence and progression 
of premalignancy on follow-up AFB. Cancer was diagnosed in 4% of 
these patients at > 6 months after the ﬁrst screening procedure. 
Conclusions: Selecting patients for lung cancer screening with AFB, 
based solely on known risk factors for lung cancer, is an efﬁcient 
means for detecting premalignant lesions. The level of persistence and 
progression of these lesions on follow-up AFB is signiﬁcant for all 
grades, even metaplasia. This suggests that metaplasia is not simply 
a transient change to the epithelium, even in former smokers, and the 
detection of metaplasia over multiple AFB examinations may confer 
the risk of a damaged or progressively worsening airway. 
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Background: Positron emission tomography (PET) has been reported 
as being useful in the assessment of indeterminate pulmonary nodules 
found on thoracic computed tomography (CT) scans in both clini-
cal and screening settings. Sensitivity and speciﬁcity for malignancy 
has been reported as ranging from 69-97% and 70-91% respectively. 
Positive and negative predictive values have been 87-90% and 71-84% 
respectively. The performance of PET is known to be reduced with tu-
mours that have relatively low metabolism or are less than 8mm in size. 
Our objective was to evaluate the utility of PET scan in CT detected 
suspicious lesions found in a lung cancer screening program.
Method: As part of several NCI sponsored chemoprevention trials 
(N01-CN-85188, PO1 CA096964-01A1, U01CA96109) thoracic CT 
scan has been incorporated into an early lung cancer detection program 
since June 2000. Volunteers recruited from the community include 
current or former smokers at least 50 years of age with a 30 pack/year 
smoking history. All suspicious lesions detected on thoracic CT scan 
that were referred for surgical resection and had a preoperative PET 
scan were evaluated. Suspicious lesions were deﬁned as those found to 
be growing or showing an increase in a solid component on serial CT 
scan, or of a large size (>10mm) at the baseline screening CT scan.
Results: A total of 25 lesions have had both a preoperative PET scan 
and surgical resection. This included 18 malignant lesions (9 with se-
rial CT growth and 9 at baseline CT) and 7 benign lesions. The mean 
size of malignant lesions was 15mm (range 7-33mm) and of benign 
lesions was 13mm (range 10-17mm). The majority of malignant lesions 
were adenocarcinoma (16/18);one squamous cell and one small cell 
carcinoma were also detected. CT appearance of the malignant lesions 
included 56%(10/18) solid lesions, 22%(4/18) semisolid lesions and 
22%(4/18) nonsolid lesions. One lesion demonstrated a pure replace-
ment growth pattern consistent with bronchioloalveolar carcinoma 
(BAC). Benign lesions included inﬂammatory lesions (5/7), amyloid 
(1/7) and hamartoma (1/7). A total of 39%(7/18) of malignant lesions 
were PET positive and 43%(3/7) of benign lesions were PET positive. 
The average size of PET positive malignant lesions was 18.6mm (range 
10-33mm) and PET negative malignant lesions was 13mm (range 7-20 
mm). Based on CT appearance, 50% of solid malignant lesions were 
PET positive and 25% of semisolid/nonsolid malignant lesions were 
PET positive. The sensitivity, speciﬁcity, positive predictive value and 
negative predictive value of PET scan were 39%, 57%, 70% and 27% 
respectively.
Conclusions: The lower performance of PET in this series compared 
to previously reported studies cannot be attributed to small size of the 
lesions or preponderance of BAC. Further clinical investigations should 
be performed for lesions that are growing or show an increase in the 
solid component on thoracic CT scan despite a negative PET.
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Background: The addition of L-BLP25 as maintenance therapy 
in patients with non-progressive stage IIIB or IV NSCLC has been 
investigated in a randomized, open-label, controlled, multi-centre phase 
IIB study. A survival beneﬁt of 4.4 months was reported in the patients 
that received L-BLP25 in addition to best supportive care (BSC) [Butts 
et al., J Clin Oncol 2005; 23: 6674-6681). In addition, in March 2006, 
a further survival analysis of this trial was conducted to identify the me-
